Revolutionize Healthcare

Exporting medicines worldwide

Our Mission

To enhance global health by manufacturing and delivering high-quality, innovative pharmaceuticals and medical devices that meet international standards. We are committed to improving lives worldwide through ethical practices, scientific excellence, and customer-focused solutions

Our Vision

To be recognized as a premier global supplier of pharmaceutical products and nutraceuticals, distinguished by our unwavering commitment to quality, innovation, and client satisfaction.

ABOUT US

Efficiency-driven Technology for Healthcare

Glatzo Pharma stands as a beacon of reliability in pharmaceutical exports and supplement manufacturing. Our operations are anchored in a steadfast commitment to regulatory compliance, ethical sourcing, and timely global delivery. Our core strength lies in our ability to procure and export a vast portfolio of finished pharmaceutical formulations, over-the-counter (OTC) products, essential medical consumables, and innovative health supplements.

Leveraging our profound understanding of international markets and robust industry partnerships, we offer our global clientele seamless access to cost-effective, high-quality products. This is complemented by our meticulous logistics management and comprehensive documentation support, ensuring a smooth and efficient supply chain

30%

Improved Patient Care

20%

Enhanced Clinical Operations

40%

Streamlined Diagnostics

Innovating Health, Globally

Products

Elevating Healthcare Solutions

We produce a comprehensive, diverse and highly complementary portfolio of medicines targeting a wide spectrum of chronic and acute treatments. Our product portfolio includes generics, branded generics, speciality, difficult-to-make technology intensive products, over-the-counter (OTC), anti-retroviral (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates. Our presence in more than 21 countries helps us in being responsive to local treatment needs while continually improving our global product offering.

Pharmaceutical Segments: We export a wide array of branded and generic formulations across critical therapeutic categories, including:

Gynaecology
Oncology
Cardiology
Orthopaedics
Dentistry
Dermatology
Neurology
Gastroenterology
Endocrinology

AI-integrated Diagnostics

Experience the power of AI in diagnostics and discover how it can enhance patient care and optimize clinical decision-making.

Patient Care Solutions

Explore our innovative patient care solutions designed to improve the overall healthcare experience and patient outcomes.

Clinical Operations Optimization

Optimize your clinical operations with our advanced solutions, ensuring efficient workflows and streamlined processes.

Healthcare Analytics

Leverage data-driven insights with our healthcare analytics solutions to make informed decisions and drive improvements in patient care.

Speciality Medications

Innovative Technology for Healthcare

Glatzo has built a portfolio of patent protected speciality medicines for global markets. Over the years, we have nurtured this evolving business through increased focus and investments. The key segments we are targeting are dermatology, ophthalmology and oncology. Our focus is on improving patient outcomes either by addressing unmet medical needs or by enhancing patient convenience through differentiated dosage forms. Our initiatives in this segment cover the entire value chain, from in-licensing early-to-late stage clinical candidates, as well as getting access to on-market patented products. Today, we are among the leading branded companies in the US with several speciality products launched in the country.

Generic Medications

We provide high quality generic and branded medicines at affordable costs to patients and doctors in more than 21 countries worldwide. Our products have the hallmark of technology-based differentiation and cover the full range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams and liquids. The therapeutic segments covered by our portfolio of over 2000 molecules include psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritional’s. In several countries, Glatzo ranks among the leading companies in these therapy areas.

Over-the-Counter Medications

We provide a range of over-the-counter (OTC) / consumer healthcare products. There are other category defining brands such as Coldact & Flustat (cold & flu), Brustan, Painamol & Paduden (analgesics), Aspenter, Aspacardin, Nudrate & Fortifikat (lifestyle OTCs), Gestid (digestives) and Chericof (cough).

Active Pharmaceutical Ingredients

We began producing Active Pharmaceutical Ingredients (APIs) in as a vital input in the manufacture of complex formulations to facilitate vertical integration. Today, our list of APIs exceeds 380 which is used in house as well as marketed to customers in over 60 countries. Our product list includes generics and complex APIs that require isolated manufacturing areas like anti-cancers, peptides, steroids, sex hormones and controlled substances, including poppy-derived opiate raw materials that are primarily used in the manufacture of analgesics, sold as both Narcotic Raw Materials (NRM) and APIs. We offer bulk actives, intermediates and services for custom synthesis.

Anti Retro Viral Medications

We offer a wide range of WHO prequalified ARV medicines. Improving access and affordability is our key objective. Our portfolio comprises bio-equivalent ARV medicines and Active Pharmaceutical Ingredients (API) manufactured at our state-of-the-art WHO prequalified manufacturing facilities in India, a PIC/S approved manufacturing facility in South Africa and a facility in Russia. Indeed, with several first-line and second line Highly Active Antiretroviral Therapy (HAART) regimens in our portfolio, we hope to contribute significantly to combating HIV/AIDS.

Join us

We provide high-quality, affordable medicines trusted by healthcare professionals and patients in over 21 countries worldwide. Glatzo is also among India’s largest and pharmaceutical company.

We have strong capabilities in developing generic and complex products with a robust pipeline of ANDAs, including high value First-to-File (FTF) opportunities. We have an established presence in Europe and key high-growth Emerging Markets (EM) like Russia, Romania, South Africa, Brazil and Malaysia.

We are in constant search of partners who match our values, work ethics and commitment to patients. We regard partnership and collaboration as an integral part of our business strategy. This important initiative is supported by a dedicated team for global business development, licensing and post-alliance management.

Our track-record of successful collaborations includes in/out licensing of products and technologies, joint ventures, as well as acquisition of assets. We offer a full range of both global and local integrated, organisational and commercial capabilities, combined with a history of successful product launches.

Generics and Differentiated Generics [505(b)2] In-licensing

We constantly seek to strengthen our presence, with a range of generic and specialty generic (505(b)2) products, in global markets.

Our primary focus is to in-license generic and differentiated generic products that are close to commercialization or in advanced stage of development for North America, Western Europe and Japan markets.

All our efforts are towards continuing growth and to achieve this we are looking to in-license technology based specialty generics such as, but not limited to, long acting injectable, liposomes, implants, drug-device combination products, oral films, etc. for US market.

For Europe, our specialty business is focusing on hospital products which can be generic products or differentiated generic products including long acting injectable, liposomes etc. offering convenience to hospitals, patients and healthcare providers.

For Japan, the focus is on generic products for hospitals including Oncology. We are also looking for acquiring long listed brands in CNS, Derma, Anti-Infectives etc. We are also looking for opportunities for partnership on distribution of authorized generics for US and Japan.

We constantly seek to establish and strengthen long term, mutually rewarding business relationship based on suitable business models like co-development, licensing or fees for service. We believe in investing in our partners and extending all technical expertise wherever is required.

Branded Business

Over the last few years, Glatzo has been focusing on branded specialty products which include New Chemical Entities, New Molecular Entities, Biologics and Novel technologies. Glatzo is actively looking into business expansion through in-licensing, M&A and out-licensing activities for branded products. Glatzo also has a strategic interest in establishing Joint Ventures and Research Partnerships with world-renowned academia and institutes.

For branded business, Glatzo is interested in expanding it footprint globally, main geographies of interest being North America, Europe, Japan and Emerging Markets.

The focus therapy areas for branded specialty business are ophthalmology, dermatology and oncology. However, being entrepreneur in nature, Glatzo also remains highly interested in high-potential breakthrough opportunities outside these therapy areas.

In-Licensing and M&A in Branded BD

Glatzo is looking for commercial, close-to-market and late-stage clinical opportunities and/or M&A in below areas:

Ophthalmology: Ophthalmic disorders involving eye surface, anterior and posterior eye segment.
Dermatology: Inflammatory and autoimmune conditions with unmet medical needs like acne, atopic dermatitis and others as well as niche indications.
Oncology: Niche indications in oncology as well as oncology conditions affecting skin.
CNS: Neurological and psychiatric conditions. Glatzo would be highly interested in expanding its pipeline portfolio of products for treatment of pain based on abuse-deterrent technology platforms and for migraine.
Orphan Indication: Glatzo would be interested in Orphan indication related to above therapy areas.

Out-Licensing in Branded BD

Glatzo is focusing on expansion of its specialty branded business worldwide. In that direction, the company has plans to establish this in either through development of in-house infrastructures or through partnerships in different geographies. Glatzo is actively seeking partnerships to develop and commercialize its various branded assets in Europe, Japan and selected Emerging Markets.

Other Therapy areas

Glatzo would be interested in business opportunities for indications complementary to its current branded specialty products where Glatzo and the partner would be able to expand the indications for those products to optimize the product potential and to provide treatment modalities of existing unmet medical needs.

Research Collaborations and Joint Ventures in Branded BD

We also have a strategic interest in establishing research collaborations and joint ventures with world-class academic institutes and industry with the vision of developing robust scientific base and adding novel breakthrough products to our portfolio which will offer unique treatments for many unmet medical needs. Glatzo is interested in entering partnerships and working with top-notch scientists in the world.